Oruka Therapeutics Inc.

NASDAQ: ORKA · Real-Time Price · USD
15.27
0.27 (1.80%)
At close: Aug 15, 2025, 2:58 PM

Oruka Therapeutics Income Statement

Financials in USD. Fiscal year is undefined.
Fiscal Year Q2 2025 Q1 2025 Q4 2024 Q3 2024 Q2 2024 Q1 2024 Q4 2023 Q3 2023 Q2 2023 Q1 2023 Q4 2022 Q3 2022 Q2 2022 Q1 2022 Q4 2021 Q3 2021 Q2 2021 Q1 2021
Period Ending Jun 30, 2025 Mar 31, 2025 Dec 31, 2024 Sep 30, 2024 Jun 30, 2024 Mar 31, 2024 Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022 Dec 31, 2021 Sep 30, 2021 Jun 30, 2021 Mar 31, 2021
Revenue
n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a
Cost of Revenue
31K 24K 27K 34K 84K 101K 111K 117K 115K 115K 114K 113K 112K 102K 91K 79K 78K 85K
Gross Profit
-31K -24K -27K -34K -84K -101K -111K -117K -115K -115K -114K -113K -112K -102K -91K -79K -78K -85K
Operating Income
-113.28M -110.73M -88.12M -59.4M -31.88M -7.98M -7.3M -7.29M -7.11M -7.57M -9.05M -13.15M -16.1M -18.51M -19.34M -18.78M -16.05M -12.53M
Interest Income
13.81M 10.4M 6.78M 2.75M 1.93M 1.98M 1.96M 2.13M 1.62M 1.13M 675K n/a n/a n/a n/a n/a n/a n/a
Pretax Income
-99.98M -102.71M -83.72M -59.03M -31.83M -6M -5.34M -5.42M -6.33M -8M -9.93M -14.43M -16.81M -18.49M -19.32M -18.77M -16.05M -12.53M
Net Income
-99.98M -102.71M -83.72M -59.03M -31.83M -6M -5.34M -5.42M -6.33M -8M -9.93M -14.43M -16.81M -18.49M -19.32M -18.77M -16.05M -12.52M
Selling & General & Admin
18.04M 15.88M 12.41M 9.13M 6.96M 6.46M 6.17M 5.94M 5.55M 5.27M 4.96M 5.39M 5.44M 5.27M 5.41M 5.61M 5.27M 4.94M
Research & Development
95.21M 94.82M 75.06M 49.6M 24.23M 788K 1.01M 1.23M 1.44M 2.19M 3.97M 7.65M 10.55M 13.13M 13.83M 13.1M 10.71M 7.5M
Other Expenses
n/a -4.39M -3.76M -3.76M -3.76M 628K n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a
Operating Expenses
113.25M 106.31M 83.71M 54.97M 27.43M 7.88M 7.18M 7.17M 7M 7.46M 8.94M 13.04M 15.99M 18.41M 19.24M 18.7M 15.98M 12.44M
Interest Expense
504K 504K 718K 718K 214K 214K n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a 2K 5K
Selling & Marketing Expenses
n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a
Cost & Expenses
63.11M 56.17M 83.74M 55.01M 27.5M 7.98M 7.3M 7.29M 7.11M 7.57M 9.05M 13.15M 16.1M 18.51M 19.34M 18.78M 16.05M 12.53M
Income Tax Expense
n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a -9K
Shares Outstanding (Basic)
42.23M 41.68M 16.79M 15.01M 14.51M 14.5M 14.42M 14.41M 14.41M 14.41M 1.2M 1.2M 1.2M 1.2M 1.2M 1.2M 1.2M 1.03M
Shares Outstanding (Diluted)
42.23M 41.68M 16.79M 15.01M 14.51M 14.5M 14.42M 14.41M 14.41M 14.41M 1.2M 1.2M 1.2M 1.2M 1.2M 1.2M 1.2M 1.03M
EPS (Basic)
-4.53 -5.25 -4.99 -4.35 -3.63 -3.56 -4.44 -4.52 -5.27 -6.66 -8.26 -12.01 -13.99 -15.4 -16.66 -18.37 -18.4 -23.08
EPS (Diluted)
-4.53 -5.25 -4.99 -4.35 -3.63 -3.56 -4.44 -4.52 -5.27 -6.66 -8.26 -12.01 -13.99 -15.4 -16.66 -18.37 -18.4 -23.08
EBITDA
-99.42M -97.11M -78.12M -53.42M -26.69M -5.9M -5.23M -5.31M -6.22M -7.88M -9.81M -14.31M -16.7M -18.39M -19.23M -18.69M -15.97M -12.44M
EBIT
-99.47M -97.14M -78.15M -53.46M -26.77M -6M -5.34M -5.42M -6.33M -8M -9.93M -14.43M -16.81M -18.49M -19.32M -18.77M -16.05M -12.52M
Depreciation & Amortization
31K 24K 27K 34K 84K 101K 111K 117K 115K 115K 114K 113K 112K 102K 91K 79K 78K 85K